ReviewImmunological reviews2011
Vaccines to combat the neglected tropical diseases.
Review in Immunological reviews, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 1 synthesis or guideline pooled it, 169 citations in OpenAlex.
- Circulating antigen tests and urine reagent strips for diagnosis of active schistosomiasis in endemic areas.The Cochrane database of systematic reviews · 2015Pooled it
- Pilot Field Trial of the EG95 Vaccine Against Ovine Cystic Echinococcosis in Rio Negro, Argentina: Second Study of Impact.PLoS neglected tropical diseases · 2015Trial
- Zoonotic Parasite Nanovaccines: Progress, Challenges, and Future Perspectives.Integrative zoology · 2026Review
- Attitudes and acceptance of vaccination against neglected tropical diseases: A multi-country study in Asia.Human vaccines & immunotherapeutics · 2025Article
- Attitudes and acceptance of mRNA-based vaccine for neglected tropical diseases: A multi-country study in Asia.Human vaccines & immunotherapeutics · 2025Article
- A Comprehensive Analysis ofPathogens (Basel, Switzerland) · 2025Review
- Individually or as a Team-The Immunological Milieu in the Lung Caused by Migrating Single-Sex or Mixed-Sex Larvae ofPathogens (Basel, Switzerland) · 2023Article
- Ensuring equity with pre-clinical planning for chlamydia vaccines.NPJ vaccines · 2023Review
- Transcriptional patterns of sexual dimorphism and in host developmental programs in the model parasitic nematode Heligmosomoides bakeri.Parasites & vectors · 2023Article
- Development of In Vitro Assays with the Canine HookwormPathogens (Basel, Switzerland) · 2023Article
- The mRNA Vaccine Technology Era and the Future Control of Parasitic Infections.Clinical microbiology reviews · 2023Review
- A Data-Driven Approach to Construct a Molecular Map ofVaccines · 2023Article
- The United States Food and Drug Administration (FDA) regulatory response to combat neglected tropical diseases (NTDs): A review.PLoS neglected tropical diseases · 2023Review
- Recent Progress in the Development of Indole-Based Compounds Active against Malaria, Trypanosomiasis and Leishmaniasis.Molecules (Basel, Switzerland) · 2022Review
- Identifying novel candidates and configurations for human helminth vaccines.Expert review of vaccines · 2021Article
- Article
- Individuals co-exposed to sand fly saliva and filarial parasites exhibit altered monocyte function.PLoS neglected tropical diseases · 2021Article
- Computational Design and Preliminary Serological Analysis of a Novel Multi-Epitope Vaccine Candidate against Onchocerciasis and Related Filarial Diseases.Pathogens (Basel, Switzerland) · 2021Article
- Characterization of a new Leishmania major strain for use in a controlled human infection model.Nature communications · 2021Article
- In-silico design of a multi-epitope vaccine candidate against onchocerciasis and related filarial diseases.Scientific reports · 2019Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 8 institutions in 2 countries.
Funding
Abstract
The neglected tropical diseases (NTDs) represent a group of parasitic and related infectious diseases such as amebiasis, Chagas disease, cysticercosis, echinococcosis, hookworm, leishmaniasis, and schistosomiasis. Together, these conditions are considered the most common infections in low- and middle-income countries, where they produce a level of global disability and human suffering equivalent to better known conditions such as human immunodeficiency virus/acquired immunodeficiency syndrome and malaria. Despite their global public health importance, progress on developing vaccines for NTD pathogens has lagged because of some key technical hurdles and the fact that these infections occur almost exclusively in the world's poorest people living below the World Bank poverty line. In the absence of financial incentives for new products, the multinational pharmaceutical companies have not embarked on substantive research and development programs for the neglected tropical disease vaccines. Here, we review the current status of scientific and technical progress in the development of new neglected tropical disease vaccines, highlighting the successes that have been achieved (cysticercosis and echinococcosis) and identifying the challenges and opportunities for development of new vaccines for NTDs. Also highlighted are the contributions being made by non-profit product development partnerships that are working to overcome some of the economic challenges in vaccine manufacture, clinical testing, and global access.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.